Detailed Study of the Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Relapsed Acute Myeloid Leukemia (Oncology) pipeline landscape.
Return of acute myeloid leukemia (AML) cells in the marrow and a decrease in normal blood cells after remission is called a relapsed acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfort in bones or joints such as knees, hips or shoulders. Predisposing factors include age, history of other blood cancers or disorders, genetic disorder and past chemotherapy or radiation treatments. Treatment includes chemotherapy with the same or different drugs used previously during treatment.
To access full report with TOC, please visit Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Relapsed Acute Myeloid Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Relapsed Acute Myeloid Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Relapsed Acute Myeloid Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 35, 35, 1, 3 and 1 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 6 and 2 molecules, respectively for Relapsed Acute Myeloid Leukemia.
Relapsed Acute Myeloid Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Relapsed Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Relapsed Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology)
- The pipeline guide reviews pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Relapsed Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Relapsed Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Relapsed Acute Myeloid Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Relapsed Acute Myeloid Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG AbbVie Inc Actinium Pharmaceuticals, Inc. ADC Therapeutics Sarl Aeglea BioTherapeutics, Inc. Agios Pharmaceuticals, Inc. Aileron Therapeutics, Inc. Amgen Inc. Arog Pharmaceuticals, Inc. Array BioPharma Inc. Astellas Pharma Inc. AstraZeneca Plc AVEO Pharmaceuticals, Inc. Bellicum Pharmaceuticals, Inc. Bio-Cancer Treatment International Limited BioLineRx, Ltd. BioSight Ltd. Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Calithera Biosciences, Inc. Celgene Corporation Cornerstone Pharmaceuticals, Inc. CSPC Pharmaceutical Group Limited CTI BioPharma Corp. Daiichi Sankyo Company, Limited Eisai Co., Ltd. Eli Lilly and Company EpiZyme, Inc. Exelixis, Inc. F. Hoffmann-La Roche Ltd. FLX Bio, Inc. FORMA Therapeutics Inc Fujifilm Corporation GlaxoSmithKline Plc GlycoMimetics, Inc. Igenica Biotherapeutics, Inc. Incyte Corporation JW Pharmaceutical Corporation Karyopharm Therapeutics, Inc. Kyowa Hakko Kirin Co., Ltd. MacroGenics, Inc. Merck & Co., Inc. Millennium Pharmaceuticals Inc NantKwest, Inc. Novartis AG Oxford BioTherapeutics Ltd Pfizer Inc. Pharma Mar, S.A. Polaris Pharmaceuticals, Inc. Seattle Genetics, Inc. Sunesis Pharmaceuticals, Inc. TaiGen Biotechnology Co., Ltd. Teva Pharmaceutical Industries Ltd. Tolero Pharmaceuticals, Inc. VioQuest Pharmaceuticals, Inc. ZIOPHARM Oncology, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 20:32
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home